Goodwin Advises Disc Medicine on $450 Million Upsized Public Offering

The Life Sciences team advised Disc Medicine (“Disc”) on its upsized underwritten public offering of 6,000,000 shares of common stock at a public offering price of $75.00 per share. The aggregate gross proceeds to Disc from this offering were $450 million, before deducting underwriting discounts and commissions and other offering expenses. Disc has also granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. The company is building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.

The Goodwin team was led by Gaby Morales-Rivera, Bill Collins, Lauren Zhang, Libby Sousa, and Julia Shaver, with invaluable assistance from Susan Lee and Krupa Zachariah.

For more information on the deal, please read the press release.